More about Aceruloplasminemia
Patients develop progressive parkinsonism with dystonia, rigidity, tremor, and bradykinesia typically beginning in young adulthood (typically 20s-40s), mimicking Parkinson's disease but with atypical features and earlier onset. Cognitive decline and dementia progress, often accompanying motor symptoms. Retinal degeneration with macular abnormalities leads to progressive vision loss and visual field defects. Hepatic iron accumulation causes cirrhosis in some patients with elevated transaminases and progressive liver dysfunction.
Keep reading about Aceruloplasminemia
Pancreatic iron deposition leads to diabetes mellitus and pancreatic insufficiency. Additional manifestations include hypogonadism and cardiac dysfunction. Serum ceruloplasmin is markedly reduced or absent (<10mg/dL, normal ~30mg/dL). Serum iron and ferritin are paradoxically elevated despite cellular iron deficiency due to impaired iron efflux. MRI shows characteristic iron accumulation predominantly in basal ganglia (globus pallidus, putamen) and substantia nigra.
What are the symptoms of Aceruloplasminemia?
These are common symptoms of Aceruloplasminemia, and how strong they are varies from person to person.
- Progressive parkinsonism and movement disorder
- Cognitive decline and dementia
- Retinal degeneration causing vision loss
- Liver disease and cirrhosis
- Diabetes mellitus from pancreatic iron accumulation
- Hypogonadism and cardiac dysfunction
Who gets Aceruloplasminemia?
Manifests in young adulthood (typically 20s-40s, range 16-45 years) with progressive neurological symptoms. Affects males and females equally with no gender predominance. Autosomal recessive inheritance requires mutations in both CP gene copies; parents are obligate carriers (heterozygotes) typically asymptomatic. Homozygous or compound heterozygous mutations cause disease.
Significantly more common in certain populations (Japan, Italy, Portugal, South Korea) where specific founder mutations documented. Extremely rare in other populations; fewer than 100 cases reported worldwide. Geographic clustering and founder mutations documented. Earlier onset in some families suggests possible genetic modifiers. Increased frequency in populations with consanguinity.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
How to get help paying for Aceruloplasminemia treatment
Charity funds and drugmaker programs for Aceruloplasminemia, checked at the source.
- Exjade (Deferasirox) · Novartis Patient Assistance Foundation
- Ferriprox (Deferiprone) · Chiesi Total Care
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Aceruloplasminemia
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Aceruloplasminemia resources
Reputable organizations and medical references for learning more about Aceruloplasminemia, including disease registries, foundation resources, and clinical guidelines.